slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 89,671-89,700
Pages 3,225
Rows per page 30
Component
89,671-89,700 of 96,741
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide highlights the progression of delivery technology enabled by the ENHANZE license.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
23
The diagram is a variation of a flywheel or infinity loop representing the integration of clinical development and disease insight.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
19
The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
08
The slide outlines a 12-week open-label study with a specific focus on treatment-resistant depression (TRD).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes trial objectives and timeline markers for both parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses EEG power spectral density analysis to demonstrate target engagement and potential for a superior safety profile (less sedation) compared to standard benzodiazepines.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
03
The slide uses a three-column layout to categorize revenue streams: Drug Discovery (yellow), Development Pipeline (orange), and Knowledge Exploration Tools (teal).BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a value-chain style flow from left to right, emphasizing the integration of diverse data types into a central knowledge graph.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
36
Includes PET scan imagery comparing baseline to post-treatment status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
45
Uses a 2x2 grid layout to present key market metrics alongside current treatment efficacy benchmarks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
47
The slide uses a funnel-like logic to narrow down the addressable market from total prevalence to the 2L+ refractory segment.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
09
The chart illustrates the bank's ability to maintain lower deposit costs than peers during interest rate cycles.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
The chart highlights Crocs' superior margin performance relative to competitors.Crocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations Beat · Business Model1 hit
11
The slide uses four donut charts to illustrate business composition.Crocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses house-shaped icons to represent growth metrics.Crocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations Beat · Traction1 hit
19
Includes a trend line and a callout for 'Transformation & Brand Re-ignition' alongside '5+ Years of Profitable Growth'.Crocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations 1 hit
22
Crocs | Investor Presentation Deck | 29 slidesCrocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations 1 hit